Psoriasis in Pregnancy: A Review

Michael Tyutyunik\textsuperscript{1}, Nahla Shihab MD\textsuperscript{2}, Mark Lebwohl MD\textsuperscript{3}

\textsuperscript{1}Research Assistant, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
\textsuperscript{2}Clinical Dermatology Fellow, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
\textsuperscript{3}Professor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

ABSTRACT
Psoriasis is a complex autoimmune disease, most commonly characterized by silvery scale erythematous plaque. During pregnancy, there is a physiologic change of immunology status, which shifts from an inflammatory state to an anti-inflammatory state, in order to avoid fetal rejection. As a result of this immunomodulatory changes, the majority of pregnant patients experience improvement of their psoriasis. The treatment of psoriasis in pregnancy can be challenging, mainly because there is only a few evidence-based studies. The objective of this paper is to review the relevant data on psoriasis in pregnancy and its treatment.

INTRODUCTION
Psoriasis is chronic inflammatory skin disease that most commonly characterized by silvery scale erythematous plaque.\textsuperscript{1,2} It may be associated with other comorbidities such as joint, ocular, and systemic disorders. The treatment of psoriasis is varied depending on the disease severity, comorbidities, and patient preference.\textsuperscript{2,3} In the case of pregnancy, treatment of psoriasis can also be challenging. Generally psoriasis improves during pregnancy, however, many pregnant patients still need treatment. Pregnant women must use caution when using any medications, and doctors must decide what treatment options are best for mother and fetus.\textsuperscript{4}

REVIEW

Immunopathology of psoriasis
Psoriasis is a complex autoimmune and autoinflammatory disease that is characterized by rapid epidermal growth resulting in a number of clinical manifestations, most commonly sharply demarcated erythematous scaling plaques.\textsuperscript{5} The major cells that play a central role in the pathogenesis of psoriasis are keratinocytes, endothelium, dendritic cells, and T cells.\textsuperscript{6} Alteration of keratinocyte function, vascular structure, innate and adaptive immune systems contribute to the manifestations of psoriasis.\textsuperscript{7} Dendritic cells are a key factor of inflammation in psoriasis, in particular, plasmacytoid dendritic cells producing interferon-alpha (IFN-alpha), which stimulate the activation of myeloid dendritic cells. Myeloid dendritic cells produce interleukin-
12 (IL-12) and IL-23, which promote the development of T-helper 1 (Th1) and Th17 cells.\textsuperscript{6,7} Th1 cells produce proinflammatory cytokines, including IFN-gamma, IL-2, and tumor necrosing factor-alpha (TNF-alpha), that have roles in inflammation and psoriasis-like changes in skin. The activation of Th17 cells stimulates the production of IL-17A and IL-22, both of them promoting keratinocyte activation and growth.\textsuperscript{7} Recent data suggest IL-17 cytokines as key factors in the development of psoriasis.

**Immunological changes during pregnancy**

The state of pregnancy has the potential to be severely detrimental to the female immune system being that the father’s foreign antigens, which are contained within the fetus, are capable of eliciting a robust immunological response from the mother. It follows, therefore, that during pregnancy, the mother’s immune responses must shift from an inflammatory state to an anti-inflammatory state, in order to avoid fetal rejection.\textsuperscript{8} Pregnant women experience an overall increase in white blood cells, mainly neutrophils. However, there is a decrease in total T cell numbers and activated T cells.\textsuperscript{9}

**Characteristics of psoriasis in pregnancy**

As a result of immunomodulatory changes of pregnancy, the majority of pregnant patients experience improvement of their psoriasis. However, some may also experience worsening of psoriasis, which is still poorly understood.\textsuperscript{10} In pregnancy, the maternal immune system is shifting toward Th2 immunity, causing a lower level of Th1 cytokines that are responsible for the inflammatory immune response in psoriasis.\textsuperscript{11}

Psoriasis is also correlated with hormonal changes that women undergo during pregnancy, with high level of estrogen and progesterone as the central players for improvement.\textsuperscript{12,13} Throughout pregnancy other hormones including human chorionic gonadotropin, glucocorticoid, prolactin, and human placental lactogen, are increased. These hormones are all known to have immunosuppressive effects, which is also a reason for improvement of psoriasis in pregnancy.\textsuperscript{10,14}

**Psoriasis treatment in pregnancy**

There are few evidence-based studies on treating psoriasis in pregnancy. Topical treatments are the most commonly recommended treatment options for pregnant women with psoriasis.\textsuperscript{15} Moisturizing agents and emollients such as petroleum jelly and mineral oil have been found to reduce psoriatic plaques. They can help reduce inflammation of the skin, reduce skin cell generation, and clear affected skin plaques.

Topical corticosteroids are first line therapy for psoriasis in pregnant patients.\textsuperscript{16} Nonetheless, there is always a risk of systemic absorption which may vary from 0.5 to 7% in intact skin, and may be greater in inflamed or damaged skin.\textsuperscript{17} Therefore, it is recommended to use low to moderate potency corticosteroids rather than potent and very potent corticosteroids in pregnant woman with psoriasis.\textsuperscript{18}

Other common topical treatments in psoriasis including salicylic acid, coal tar and tazarotene, are not recommended during pregnancy.\textsuperscript{16} Calcipotriene is also not recommended in pregnancy (pregnancy category C). However, if there is no other alternative treatment, limited use of topical calcipotriene is still permissible.\textsuperscript{19}
Phototherapy with narrowband ultraviolet B (NB-UVB) is the second-line treatment for pregnant women with psoriasis. UVB, which is present in natural sunlight, is an effective treatment for psoriasis as the light can penetrate the layers of the skin and help reduce the growth of affected skin cells. Phototherapy, both narrowband and broadband UVB, is considered safe and effective in pregnancy due to limited penetration to the mother’s skin. The data for phototherapy during pregnancy are limited, nevertheless it has not been associated with any increase risk of abnormal delivery or fetal abnormalities. The only consideration of phototherapy in pregnancy is the potential photodegradation of maternal folate, which can cause neural tube defects in the fetus. Therefore, folic acid supplementation is even more highly recommended for these patients.

Nowadays biologic agents are the cornerstones in the treatment of psoriasis. Although this treatment shows promise in treating the disease, the risk of alteration of the immune system is the major concern particularly in pregnant patient. Currently there are four classes of biologic agents that are approved for psoriasis, tumor necrosis factor inhibitors (TNFi), an IL-12/23 inhibitor, IL-17 inhibitors, and IL-23 inhibitors. Fundamentally, these therapies are monoclonal antibodies or fusion proteins which block cytokines or receptors associated with psoriasis, which play roles in the pathogenesis of psoriasis. The potential antibody transfer from mother to fetus is the major concern that limits the use of biologic agents in pregnancy. Monoclonal antibody can actively cross the placenta with the help of neonatal fragment crystallizable (Fc) receptor that are found on trophoblasts, especially during second and third trimesters. This transfer may result in immunosuppression of the newborn, resulting in higher risk for infection. However, pregnant women are usually excluded from clinical trials including study for biologic agents. Therefore, knowledge about safety of these treatments are very limited. Among TNFi, certolizumab pegol is the only biologic agent that has supporting data of safety to be used in both pregnancy and breastfeeding, due to its lack of Fc portion. Without the Fc portion, certolizumab is not actively transported across the placenta. Ustekinumab, an IL-12/23 inhibitor, has very limited data with only few case reports and case series that showed no increased risk of congenital defects or adverse events in pregnant women. Both IL-17 inhibitors (secukinumab, ixekizumab), and IL-23 inhibitors (tildrakizumab, guselkumab, risankizumab) have extremely limited data with no human studies for psoriasis in pregnancy.

Psoriasis is a chronic skin condition with a variety of treatments that impacts conception, pregnancy, and postpartum care. While there are some treatments already known to be safer than others, the precise effects of psoriasis on pregnancy are still mostly incomplete due to insufficient available studies. A large scale of systematic review in the treatment of psoriasis in pregnancy is still needed.

**CONCLUSION**
Conflict of Interest Disclosures: None

Funding: None

Corresponding Author:
Nahla Shihab, MD
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
5 E 98th street, New York, NY, 10029
Phone: 212-241-9728
Fax: 212-987-1177
Email: nahla.shihab@gmail.com

References:
1. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? Journal of the American Academy of Dermatology. 2000 Aug 1;43(2):281-5.

2. Feldman SR. Epidemiology, clinical, manifestations, and diagnosis of psoriasis. [Updated 2019 Aug 6]. In: UpToDate [Internet]. Available from: https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis (accessed 31 October 2019).

3. Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Annals of the rheumatic diseases. 2005 Mar 1;64(suppl 2):ii83-6.

4. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Archives of internal medicine. 2000 Mar 13;160(5):610-9.

5. Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. British journal of nursing. 2008 Mar 13;17(5):284-90.

6. Reali E, Brembilla NC. Editorial: Immunology of psoriatic disease. Frontiers in Immunology. 2019 Mar 29;10(657):1-3.

7. Blauvelt A, Esh B. Patophysiology of plaque psoriasis. [Updated 2019 Apr 30]. In: UpToDate [Internet]. Available from: https://www.uptodate.com/contents/patophysiology-of-plaque-psoriasis (accessed 31 October 2019).

8. Robinson, D. P., & Klein, S. L. (2012). Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Hormones and behavior, 62(3), 263-271.

9. MacLean MA, Wilson R, Thomson JA, Krishnamurthy S, Walker JJ. Immunological changes in normal pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1992 Feb 28;43(3):167-72.

10. Hoffman MB, Farhangan M, Feldman S. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev. Clin. Immunol. 11(6), 709–720 (2015)

11. Yip L, McCluskey J, Sinclair R. Immunological aspects of pregnancy. Clin Dermatol 2006;24(2):84–7

12. Boyd AS, Morris LF, Phillips CM, et al. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996;35(3):169–72

13. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post-partum. Archives of dermatology. 2005 May 1;141(5):601-6.

14. Nolten WE, Rueckert PA. Elevated free cortisol index in pregnancy: possible regulatory mechanisms. Am J Obstet Gynecol 1981;139(4):492-8

15. Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ. 2007 Jun 7;334(7605):1218-20.

16. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67(3):459-77

17. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol 2012;59(5):460-4

18. Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol. 2011;165(5):943–952

19. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014;70(3):401. e1–e14

20. Vena GA, Cassano N, Bellia G, Colombi D. Psoriasis in pregnancy: challenges and solutions. Psoriasis: Targets and Therapy 2015;5:83-95.

21. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59(2):295-315

22. El-Saie LT, Rabie AR, Kamel MI, Seddeik AK, Elsaie ML. Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis. Lasers Med Sci. 2011;26(4):481–485.
23. Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. The Journal of clinical and aesthetic dermatology. 2010 Aug;3(8): 20.

24. Story, C.M. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 1994, 180, 2377–81

25. Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21–5.

26. European Medicines Agency. Certolizumab pegol (Cimzia) summary of product characteristics [Internet]. [cited 2019 November 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-productinformation_en.pdf; 2019.

27. Watson N, Wu K, Farr P, Reynolds NJ, Hampton PJ. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2018;180(1):195-6.